Information Provided By:
Fly News Breaks for December 6, 2018
PTGX
Dec 6, 2018 | 07:50 EDT
Nomura Instinet analyst Christopher Marai started Protagonist Therapeutics with a Buy rating and $13 price target. The analyst believes Protagonist is trading at a "steep discount," having sold off 69% year-to-date following an "erroneous" Phase 2 trial futility assessment for PTG-100, an oral alpha4beta7 integrin antagonist peptide.